Ahmed Elkhanany

That looks so much fun. The "no federal funds" hurt my heart!

Also as succinctly summarized here:

Fantastic team that I had the pleasure of working with. Looking great @grocquemd.bsky.social. Noha needs BluSky account! Miss you all.

Trump hits NIH with ‘devastating’ freezes on meetings, travel, communications, and hiring Researchers facing

⏱️ The next cancer cure is on hold.

⁦‪@NIH‬⁩ grants invest in future science gains that pay back for our citizens at a rate of more than 2:1 in economic activity.

We are losing the battle for discovery.

Very timely. Statement from General Surgeon out now recommending placing warning labels on all acholgoic products. www.hhs.gov/surgeongener...

Thank you so much for sharing these updates routinely for us to know

Question: Is there a way of subscribing to this as a mail list outside of DFCI?

a blue speech bubble with the words speak your mind ALT: a blue speech bubble with the words speak your mind

#SABCS24 #bcsm #OncSky #MedSky

Following up with a few resources from FDA-@abreastcancer session today for #breastcancer #advocacy community

Someone asked for email to report misleading drug ads: BadAd@fda.hhs.gov

/1

@oncoalert.bsky.social

Something sounds different in this #SABCS24 session. The science here is a little more engaging 😁.

Very true. I think cross talk of HER2 and ER has been very poorly addressed. Blocking HER2 up-regulates ER expression and mandates ER blockade. Yet, very little mention in NCCN as an afterthought!

PRACTICE CHANGING findings from PATINA presented by Dr. Metzger from @dfcibreastonc.bsky.social
- n=518 HR+/HER2+ mBC
- all received THP followed by HP+ET +/- palbo
- PFS was 29 vs 44 months with palbo
- Tox consistent with prior studies

Hyping for my smart dear friend @yabdoumd.bsky.social from UNC, who is moderating Poster Spotlight Session 9: ctDNA Uses for Minimal Residual Disease Testing, Tumor Evolution, and Novel Technologies. Tomorrow at 7 AM at Stars at Night 3-4

#SABCS2024
#bcsm
@sabcs.bsky.social

Absolutely important. “Shared” decision requires active effort by oncologists to simplify, relate and iterate findings, while not encumbering patients with nuances.

Another great study run by TBCRC and lead by my dear colleague Dr. Julie Nangia at @bcmhouston.bs. #042 used Ruxolitinib for 10-20 days b4 surgery to inhibit pSTAT5 pathway in premalig AH/CIS (ductal/lobular). 1ry endpoint is apoptosis by Caspase3 drop pending. Congrats

#SABCS24
#bcsm

Sobering data on 7-year IBC outcome from @mdanderson.bsky.social presented by superstar Dr. Azadeh Nasrazadani. 7-year OS % 7, 24, 50, 55 in TNBC, ER+ HER2-, ER- HER2+ and ER+HER2+. CDK4/6i benefit low compared with historic cohorts. @naborala.bsky.social we need better Rx.

#SABCS24
#bcsm

“It is impressive that the combination [of imlunestrant and abemaciclib] seems to tower above the rest” — @DrHalBurstein
sharing his self-proclaimed dreaded cross trial comparison (students, biostatisticians: *avert your eyes*) #SABCS24 @oncoalert.bsky.social

#EMBER3

Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut

However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1

* note prior CDK not required

#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social

A nice poster on TDxD resistance presented by my dear friend Mohamed Gouda from MDACC. Almost 1/3rd of Pts lost HER2 IHC, and another 1/3 decreased transcript.

Did PAM50 change?

#SABCS24
#bcsm

10 year follow up on OlympiA shows persistent benefit in iDFS, OS. #SABCS24 @oncoalert.bsky.social

Dr Luca Malorni presented very thought provoking TOUCH study in ER/HER2+ with neoadj HP/Taxol vs HP/Palbo Letrozole. pCR 32.9 vs 33.3%. In high RBsig, Palbo/AI did better!

Another no-chemo Rx next to KRISTINE. Qs: PAM50 role? CDK/ET replacing Taxol in NACT? What about CDK in ABC?

#SABCS24
#bcsm

Great data on PADMA presented by Dr. Loibl in 1st L HR+ MBC btw Chemo + maintenance ET vs. Palbo + ET. Palbo more than doubled time to treatment failure (6 vs 17 months)

Same data in RIGHT CHOICE with PFS 21.8 vs 12.8 months in RiboET vs CT. No more chemo 1st L!
#SABCS24
#bcsm
@sabcs.bsky.social

Great stepwise approach. Also good reminder that topical estrogen therapy did NOT demonstrate increased risk of recurrences per multiple trials incl Cold et al JNCI 2022 and metaanalysis by Beste et al AJOG 2024

#sabcs24
#bcsm

An important money slide in discordance of variants between cfDNA and tumor testing. Panel by stellar Dr. Ellen Landsberger who shared some tough Qs on utility of cfDNA from Pt advocates POV.

Take home: Breast CA has high rate of novel variants on cfDNA not on tumor

#SABCS24
@sabcs.bsky.social

OFS for fertility perservation is severely underutilized. AYA discussion with young Pts is paramount & need routine workflow

On separate note, there remains a gap in using OFS for HR+ HER2+. Data are a little different (T/OFS better than E/OFS) but they were small percent of population.

#SABCS24

Everyday there is at least one TBCRC presentation in #SABCS24. Such a wonderful consortium and amazing dedicated investigators. Since inception, 64 breast trials (and counting). @hoperugo.bsky.social @ptarantinomd.bsky.social @meghanflanigan.bsky.social #bcsm

I have to salute #SABCS24 on the amazing tech platform site and app at events.hubilo.com/sabcs2024/home and at play.google.com/store/apps/d.... The live streaming, almost instant replayability of sessions, note-taking. Please make best use of the site/app (especially for live viewing)

This was a wonderful session. Highly recommend to rewatch for those who have tough time where to start applying for funds. Foundational, NIH, and industry venues. Also internal CCSG funds and SPORE CDA. @stolaney1.bsky.social @Minetta Liu, @Larissa Korde @Brenda Ernst #SABCS24 #bcsm

I swear for a second there I panicked like, "No way I missed 2024 already?" :)

Race and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in the Randomized RxPONDER Trial AbstractBackground. The phase III RxPONDER trial has impacted treatment for node-positive(1-3), hormone receptor-positive, HER2-negative breast cancer with

Impressive work by SWOG and RxPONDER team including Kevin Kalinsky and my dear friend Yara Abdou. Both IDFS & DRFS worse for black Pts vs. whites (91.6% vs 87.1% & 95.8% vs 91.0%). Chemotherapy efficacy is same. BMI played role in outcome @oncoalert.bsky.social #bcsm #oncosky. tinyurl.com/eptu2pap

Genome-wide association analyses in Nature Genetics provide insights into the molecular etiology of dilated cardiomyopathy, which may inform the design of genetic testing strategies and may facilitate the development of targeted therapeutics. https://go.nature.com/4fIkNmh

Genome-wide association analyses in Nature Genetics provide insights into the molecular etiology of dilated cardiomyopathy, which may inform the design of genetic testing strategies and may facilitate the development of targeted therapeutics. https://go.nature.com/4fIkNmh 🧪